Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research

Research in our Department focuses on a wide variety of aspect of children's health. We study the neuroscience of pain in infants, HIV, immunology, haematology, gastroenterology, neuromuscular diseases and vaccinology.

Find out more

Teaching

The Department of Paediatrics is involved in medical sciences teaching in Paediatrics for Undergraduate students of the University of Oxford Medical School, as well as running a number of Postgraduate programmes.
Find out more

Get involved

The research in our Department affects many children and their parents. Here you can find out what we do to reach out, from events that we have organised in the past to information about patient involvement schemes.
Find out more

What's new

Oxford's coronavirus vaccine received regulatory approval from the MHRA

Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine

The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Necrotic tissue damage as a result of Duchenne muscular dystrophy

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

More news

Connect with us

How does herd immunity work?

‘Herd immunity’ or 'herd protection' gives protection to vulnerable people such as newborn babies, elderly people and those who are too sick to be vaccinated.

#StartedinOxford

The Paediatric Neuroimaging group are measuring brain activity when babies experience pain #StartedinOxford.

How do babies feel pain?

How do vaccines work?

This short animation explains how vaccines enable the body to make the right sort of antibodies to fight a particular disease.

Featured

Oxford-Harrington Rare Diseases Centre

ORDI helps to facilitate relationships between Oxford’s researchers, clinicians, and the wider rare disease community.

About ORDI

Vaccine Knowledge Project

The Vaccine Knowledge Project provides independent. authoritative and accessible scientific information about vaccination.

Explore VKP

MDUK Oxford Neuromuscular Centre

We drive the development of novel experimental therapies and increase national clinical trial capacity in neuromuscular diseases.

Read more

Paediatric Neuroimaging

The Paediatric Neuroimaging Group aims to improve understanding of human brain development, with a particular focus on improving the treatment of infant pain.

Read more

For access to staff pages and student pages, please remember to log into the site with your Oxford Single Sign on at the top right hand side of the page.

If you're not immune to measles you can catch it just by going into a room up to 2 hours after an infected person has left it!